MS Pharmaceutical Sciences
Chemistry and Biochemistry
College of Science & Mathematics
Yang, Catherine F.
Caputo, Gregory A.
Beta-amino alcohols, Cross-linkers, Cyanopyrrolidines, Diabetes, Dipeptidyl Peptidase-IV, Peanut allergy
Food allergy; Allergy desensitization; Diabetes--Research
There is an increase in prevalence of peanut allergy, especially in the western world. The only current treatment for peanut allergy is avoidance of peanut from diet and contact. Additionally, there is currently no specific vaccine that can be taken to decrease peanut allergies. The method of desensitizing a person allergic to peanut allergy is deemed unsafe as the smallest amount of peanut can trigger an anaphylaxis reaction. Thus, various allergoids were created by modifying major peanut protein allergen Ara h2 using various cross-linkers and modification agents in order to disrupt the binding surface epitopes of the antigen to antibody.
Diabetes is also a growing problem that affects millions of people globally. Having diabetes is known to lead to various morbidity as well which can be detrimental to the patient and a burden to the economy. Various drugs are available as monotherapy for diabetes; however, we aimed to develop dual acting compounds that would not only control type 2 diabetes but also commonly associated diagnosis of hypertension as well. Thus, we have successfully synthesized and tested compounds in vitro as effective dipeptidyl peptidase-IV (DPP-IV) inhibitors and potentially effective in treating hypertension (future study) associated with diabetes by utilizing cyanopyrrolidines and Beta-amino alcohols scaffolds in the structure, respectively.
Patel, Savan V., "Development of novel therapeutic approaches: (I) Targeting allergic responses to peanuts and (II) Inhibition of DPP-IV enzyme involved in diabetes" (2017). Theses and Dissertations. 2433.